Hepatic fas antigen expression before and after interferon therapy in patients with chronic hepatitis C

被引:42
作者
Okazaki, M [1 ]
Hino, K [1 ]
Fujii, K [1 ]
Kobayashi, N [1 ]
Okita, K [1 ]
机构
[1] YAMAGUCHI UNIV,SCH MED,DEPT VIROL & PARASITOL,UBE,YAMAGUCHI 755,JAPAN
关键词
Fas antigen; chronic hepatitis C; interferon therapy; immunohistology;
D O I
10.1007/BF02100142
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
To assess the relationship between hepatitis C virus infection and Fas antigen expression on hepatocytes, we examined changes in hepatic Fas antigen expression in the presence or absence of active hepatitis C virus infection. Twenty patients with chronic hepatitis C infection were treated with interferon and underwent pre- and posttreatment liver biopsies. Patients were classified according to the absence (group A; n = 9) or the presence (group B; n = 11) of hepatitis C virus RNA (HCV-RNA) in the liver after interferon therapy. An immunohistochemical assay showed Fas antigen staining in hepatocytes membranes and cytoplasm with expression concentrated mainly in periportal areas. The percentage of Fas-positive cells in the liver before treatment was not different between group A (39.5 +/- 19.1%) and group B (32.5 +/- 15.6%). Hepatic Fas expression was reduced significantly after treatment (24.3 +/- 10.6%) compared with the pretreatment values in group A (p < 0.05) but not in group B (25.9 +/- 16.9%). There was no significant difference between the two groups in the degree of histologic improvement. These results suggest that hepatic Fas expression is associated with persistent infection of hepatitis C virus.
引用
收藏
页码:2453 / 2458
页数:6
相关论文
共 28 条
[1]   T-CELL RECEPTOR-INDUCED FAS LIGAND EXPRESSION IN CYTOTOXIC T-LYMPHOCYTE CLONES IS BLOCKED BY PROTEIN-TYROSINE KINASE INHIBITORS AND CYCLOSPORINE-A [J].
ANEL, A ;
BUFERNE, M ;
BOYER, C ;
SCHMITTVERHULST, AM ;
GOLSTEIN, P .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (10) :2469-2476
[2]   SINGLE-STEP METHOD OF RNA ISOLATION BY ACID GUANIDINIUM THIOCYANATE PHENOL CHLOROFORM EXTRACTION [J].
CHOMCZYNSKI, P ;
SACCHI, N .
ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) :156-159
[3]  
COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.iy.10.040192.001411
[4]  
DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629
[5]  
FALK MH, 1992, BLOOD, V79, P3300
[6]   SERIAL ASSAY OF HEPATITIS-C VIRUS-RNA IN SERUM FOR PREDICTING RESPONSE TO INTERFERON-ALPHA THERAPY [J].
HINO, K ;
OKUDA, M ;
KONISHI, T ;
ISHIKO, H ;
OKITA, K .
DIGESTIVE DISEASES AND SCIENCES, 1995, 40 (01) :14-20
[7]  
HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606
[8]   TREATMENT OF CHRONIC NON-A,NON-B HEPATITIS WITH RECOMBINANT HUMAN ALPHA-INTERFERON - A PRELIMINARY-REPORT [J].
HOOFNAGLE, JH ;
MULLEN, KD ;
JONES, DB ;
RUSTGI, V ;
DIBISCEGLIE, A ;
PETERS, M ;
WAGGONER, JG ;
PARK, Y ;
JONES, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (25) :1575-1578
[9]   THE POLYPEPTIDE ENCODED BY THE CDNA FOR HUMAN CELL-SURFACE ANTIGEN FAS CAN MEDIATE APOPTOSIS [J].
ITOH, N ;
YONEHARA, S ;
ISHII, A ;
YONEHARA, M ;
MIZUSHIMA, S ;
SAMESHIMA, M ;
HASE, A ;
SETO, Y ;
NAGATA, S .
CELL, 1991, 66 (02) :233-243
[10]   SUPPRESSION OF HEPATITIS-C VIRUS-RNA BY INTERFERON-ALPHA [J].
KANAI, K ;
IWATA, K ;
NAKAO, K ;
KAKO, M ;
OKAMOTO, H .
LANCET, 1990, 336 (8709) :245-245